Johanna Maria van Dongen

Johanna Maria van Dongen

Auto-generated profile, based on publicly available information

Johanna Maria van Dongen

Department of Health Sciences & EMGO+ Institute for Health and Care Research, Faculty of Earth & Life Sciences, VU University Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2017 in JAMA
Verified
Journal Article
Open access
PDF file
JJJohan N. S. Juch
Johan N. S. Juch
EMEsther T. Maas
Esther T. Maas
RORaymond Ostelo
Raymond Ostelo
JGJ. George Groeneweg
J. George Groeneweg
JKJan-Willem Kallewaard
Jan-Willem Kallewaard
MTMaurits W. van Tulder
Maurits W. van Tulder
Low back pain causes more disability than any other condition and has major social and economic consequences.1-3 In the Netherlands (16.5 million residents) the cost of low back pain was estimated at €3.5 billion (US $3.9 billion) in 2007, and the majority of the costs were attributable to patients with chronic low back pain. In the United States (326 million residents), the costs of low back pain have not been recently estimated; however, a study by Dieleman et al4 evaluated health care spending from 1996 to 2013 in the United States and estimated the health care spending on low back and neck pain at $87.6 billion.

20 April 2018 in British Journal of Sports Medicine
Verified
Journal Article
Closed access
PDF file
GMGisela Cristiane Miyamoto
Gisela Cristiane Miyamoto
CLChung-Wei Christine Lin
Chung-Wei Christine Lin
CCCristina Maria Nunes Cabral
Cristina Maria Nunes Cabral
JDJohanna M van Dongen
Johanna M van Dongen
MTMaurits W van Tulder
Maurits W van Tulder
Objective To investigate the cost-effectiveness of exercise therapy in the treatment of patients with non-specific neck pain and low back pain. Design Systematic review of economic evaluations. Data sources The search was performed in 5 clinical and 3 economic electronic databases. Eligibility criteria for selecting studies We included economic evaluations performed alongside randomised controlled trials. Differences in costs and effects were pooled in a meta-analysis, if possible, and incremental cost-utility ratios (ICUR) were descriptively analysed. Results Twenty-two studies were included. On average, exercise therapy was associated with lower costs and larger effects for quality-adjusted life-year (QALY) in comparison with usual care for subacute and chronic low back pain from a healthcare perspective (based on ICUR). Exercise therapy had similar costs and effect for QALY in comparison with other interventions for neck pain from a societal perspective, and subacute and chronic low back pain from a healthcare perspective. There was limited or inconsistent evidence on the cost-effectiveness of exercise therapy compared with usual care for neck pain and acute low back pain, other interventions for acute low back pain and different types of exercise therapy for neck pain and low back pain. Conclusions Exercise therapy seems to be cost-effective compared with usual care for subacute and chronic low back pain. Exercise therapy was not (more) cost-effective compared with other interventions for neck pain and low back pain. The cost-utility estimates are rather uncertain, indicating that more economic evaluations are needed. Registration PROSPERO, CRD42017059025.

17 September 2019 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
EME. N. Mutubuki
E. N. Mutubuki
YBY. Beljon
Y. Beljon
EME. T. Maas
E. T. Maas
FHF. J. P. M. Huygen
F. J. P. M. Huygen
RORaymond Ostelo
Raymond Ostelo
JDJ. M. van Dongen
J. M. van Dongen
Purpose: Previous studies found higher levels of pain severity and disability to be associated with higher costs and lower health-related quality of life. However, these findings were based on cross-sectional data and little is known about the longitudinal relationships between pain severity and disability versus health-related quality of life and costs among chronic low back pain patients. This study aims to cover this knowledge gap by exploring these longitudinal relationships in a consecutive cohort.Methods: Data of 6316 chronic low back pain patients were used. Measurements took place at 3, 6, 9, and 12 months. Pain severity (Numeric pain rating scale; range: 0–100), disability (Oswestry disability index; range: 0–100), health-related quality of life (EQ-5D-3L: range: 0–1), societal and healthcare costs (cost questionnaire) were measured. Using linear generalized estimating equation analyses, longitudinal relationships were explored between: (1) pain severity and health-related quality of life, (2) disability and health-related quality of life, (3) pain severity and societal costs, (4) disability and societal costs, (5) pain severity and healthcare costs, and (6) disability and healthcare costs.Results: Higher pain and disability levels were statistically significantly related with poorer health-related quality of life (pain intensity: − 0.0041; 95% CI − 0.0043 to − 0.0039; disability: − 0.0096; 95% CI − 0.0099 to − 0.0093), higher societal costs (pain intensity: 7; 95% CI 5 to 8; disability: 23; 95% CI 20 to 27) and higher healthcare costs (pain intensity: 3; 95% CI 2 to 4; disability: 9; 95% CI 7 to 11).Conclusion: Pain and disability were longitudinally related to health-related quality of life, societal costs, and healthcare costs. Disability had a stronger association with all outcomes compared to pain.

1 July 2018 in The Lancet
Verified
Journal Article
Closed access
EMEva van der Meij
Eva van der Meij
JAJohannes R Anema
Johannes R Anema
WLWouter K G Leclercq
Wouter K G Leclercq
MBMarlies Y Bongers
Marlies Y Bongers
ECEsther C J Consten
Esther C J Consten
JHJudith A F Huirne
Judith A F Huirne

1 February 2019 in Gut
Verified
Journal Article
Closed access
PDF file
EGE Joline de Groof
E Joline de Groof
TSToer W Stevens
Toer W Stevens
EEEmma J Eshuis
Emma J Eshuis
TGTjibbe J Gardenbroek
Tjibbe J Gardenbroek
JBJudith E Bosmans
Judith E Bosmans
CPCyriel Y Ponsioen
Cyriel Y Ponsioen
Objective Evaluate the cost-effectiveness of laparoscopic ileocaecal resection compared with infliximab in patients with ileocaecal Crohn’s disease failing conventional therapy. Design A multicentre randomised controlled trial was performed in 29 centres in The Netherlands and the UK. Adult patients with Crohn’s disease of the terminal ileum who failed >3 months of conventional immunomodulators or steroids without signs of critical strictures were randomised to laparoscopic ileocaecal resection or infliximab. Outcome measures included quality-adjusted life-years (QALYs) based on the EuroQol (EQ) 5D-3L Questionnaire and the Inflammatory Bowel Disease Questionnaire (IBDQ). Costs were measured from a societal perspective. Analyses were performed according to the intention-to-treat principle. Missing cost and effect data were imputed using multiple imputation. Cost-effectiveness planes and cost-effectiveness acceptability curves were estimated to show uncertainty. Results In total, 143 patients were randomised. Mean Crohn’s disease total direct healthcare costs per patient at 1 year were lower in the resection group compared with the infliximab group (mean difference €−8931; 95% CI €−12 087 to €−5097). Total societal costs in the resection group were lower than in the infliximab group, however not statistically significant (mean difference €−5729, 95% CI €−10 606 to €172). The probability of resection being cost-effective compared with infliximab was 0.96 at a willingness to pay (WTP) of €0 per QALY gained and per point improvement in IBDQ Score. This probability increased to 0.98 at a WTP of €20 000/QALY gained and 0.99 at a WTP of €500/point of improvement in IBDQ Score. Conclusion Laparoscopic ileocaecal resection is a cost-effective treatment option compared with infliximab. Clinical trial registration number Dutch Trial Registry NTR1150; EudraCT number 2007-005042-20 (closed on 14 October 2015).

25 August 2011 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
JDJ. M. van Dongen
J. M. van Dongen
KPK. I. Proper
K. I. Proper
MWM. F. van Wier
M. F. van Wier
ABA. J. van der Beek
A. J. van der Beek
PBP. M. Bongers
P. M. Bongers
MTM. W. van Tulder
M. W. van Tulder